Although President Trump has made California a favored object of scorn, the Golden State has put itself on a path to help patients better rein in Big Pharma price gouging on prescription drugs in a way that Washington hasn’t. California lawmakers have given the green light for the state to leap into making generic drugs, notably  affordable insulin to assist diabetics.

The state legislative season ended with a bill, advancing to Gov. Gavin Newsom for his signature by Sept. 30. The bill orders California’s top health agencies by January to partner with existing makers to develop and produce generics and biosimilars. As the Los Angeles Times reported of the California pharmaceuticals plan detailed in SB-852:

“Under the measure, state-developed generics would be ‘widely’ available to public and private purchasers within California. Taxpayers would pick up the costs — roughly $1 million to $2 million in startup funding, plus ongoing staff costs estimated in the low hundreds of thousands of dollars annually, according to a state fiscal analysis. It’s unclear which drugs the state would make or procure, though it would target drugs that could produce the biggest cost savings for the state and consumers.